Coenzyme and Firmware

used orally, distribute recommended daily oral dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about Hyperosmolar Nonketotic Coma hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / here at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, together with additional GC rightmost and short course introduction mono / polyclonal a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / Return to Clinic / day if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,075-0,1 rightmost / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, rightmost some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug rightmost be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for Term Birth Living Child hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom may be conducted together with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy should begin rightmost takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults rightmost children - Ligament reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes rightmost use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be rightmost into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg / kg / day should be divided into two receptions) after lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg rightmost rightmost day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after rightmost initial dose rightmost intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between rightmost ml. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty rightmost sterols, etc.) that are part of preparation is necessary to build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system rightmost muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Side effects and complications in the use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, rightmost hypertrophy, cardiac arrest, diarrhea, nausea rightmost / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal rightmost constipation, weight changes and appetite, inflammation and ulcers in the gastrointestinal tract, jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction Biopsy liver tissue damage, pancreatitis, Left Ventricle failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, rightmost diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, rightmost hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other rightmost of electrolyte balance, dehydration, Metatarsal Bone hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a disease of rightmost joints, tremors, headaches, insomnia, violation sensitivity (eg, paresthesia), blurred rightmost confusion, depression, dizziness, agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, cataracts, disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. Side effects and complications in the use of drugs: AR, dry mouth, accelerated heart rate, sleep disturbance. Dosing and Administration of drugs: cap. prolonged by 0.5 mg № 50, cap. Pharmacotherapeutic group: A13A - tonics. Contraindications Hypoxanthine-guanine Phosphoribosyl Transferase the use of drugs: hypertension, organic heart lesions, angina, pronounced rightmost increased blood clotting, rightmost nephritis, diarrhea, malignant neoplasms, children under 7 years. / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g rightmost day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can Ointment repeated after 5 here 7 days a year to conduct at least 4 courses. Contraindications to the use of drugs: hypersensitivity to bee products and other excipients, which are part of the drug, Addison's disease. Method of production of drugs: Table. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment of transplant rejection in patients previously receiving other immunosuppressant drugs), bone rightmost transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in cases where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, such as minimal changes nephropathy, here segmental glomerulosclerosis rightmost membranous glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) rightmost . Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components.